कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन और नॉरएथिस्टेरोन का इंटरैक्शन

CONTRAINDICATIONS Progestin-only oral contraceptives (POPs) should not be used by women who currently have the following conditions: • Known or suspected pregnancy • Known or suspected carcinoma of the breast.

Norethindrone tablets do not contain estrogen and, therefore, this insert does not discuss the serious health risks that have been associated with the estrogen component of combined oral contraceptives (COCs).

The healthcare professional is referred to the prescribing information of combined oral contraceptives for a discussion of those risks.

The relationship between progestin-only oral contraceptives and these risks is not fully defined.

Irregular Genital Bleeding Irregular menstrual patterns are common among women using progestin-only oral contraceptives.

• Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists ( 5.1 )

The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27–1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products.

Drugs Containing Progestins, Estrogens or Estrogen Agonist/Antagonists DUAVEE contains conjugated estrogens and bazedoxifene, an estrogen agonist/antagonist.

Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists.